Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- Acronyms POINT
- 29 Mar 2022 Planned End Date changed from 12 Jun 2027 to 24 Mar 2028.
- 29 Mar 2022 Planned primary completion date changed from 12 Sep 2024 to 24 Sep 2025.
- 29 Mar 2022 Status changed from not yet recruiting to recruiting.